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T1a prostate cancers (cancer found incidentally in transurethral resection, <5% of the tissue) are 
indolent tumors of the transition zone. The overexpression of ERG and the inactivation of PTEN 
have been shown to be important drivers of carcinogenesis in large series of prostate cancer, but 
the genetics of transition zone tumors have not been well characterized. We evaluated the status 
of ERG and PTEN in formalin-fixed paraffin-embedded tissue using immunohistochemical and 
FISH analysis in 54 T1a transition zone tumors. The protein expression of ERG was determined 
using a rabbit monoclonal antibody and nuclear staining was scored as positive or negative. The 
genomic status of ERG was determined using 3 colored FISH using an ERG-TMPRSS2 tri-color 
probe set. The protein expression of PTEN was determined using a rabbit monoclonal antibody 
and cytoplasmic and nuclear staining was scored as positive or negative. The genomic status of 
PTEN was determined using dual color FISH with a PTEN probe and a CEP10 probe. We found 
ERG rearrangement in 2 of 54 tumors (4%), one with protein overexpression by 
immunohistochemistry. PTEN inactivation was seen in 13 of 54 tumors (24%). Nine of the 13 
PTEN alleles were inactivated by hemizygous deletion. No homozygous PTEN deletion was 
observed. PTEN deletion and ERG rearrangement were mutually exclusive. ERG rearrangement 
was rare compared to peripheral zone tumors and to PTEN inactivation in T1a transition zone 
tumors.  
 
 
Introduction 
Adenocarcinomas of the prostate gland arise within different anatomic zones that have 
varying clinical and molecular characteristics.[1,2] The vast majority of clinically significant 
prostatic adenocarcinomas arise in the peripheral zone, which have been widely investigated. 
Au
tho
r M
an
us
cri
pt
Transition zone tumors are estimated to make up 16-20% of all prostate tumors, but these tumors 
have been less extensively studied. Compared to peripheral zone tumors, transition zone tumors 
have a lower Gleason scores, lower Ki-67 labeling indices, less extraprostatic extension, seminal 
vesicle invasion, and lymphovascular invasion, suggesting they may have a limited malignant 
potential.[1-4] However, approximately 20% of transition zone tumors progress to disease that 
invades beyond the prostate, and approximately 5% have lymph node metastases.[5] Currently, 
there is no method to predict which transition zone tumors will follow an aggressive course.  
Recent discoveries have shown that peripheral zone tumors show a high prevalence of 
TMPRSS2–ERG gene fusions and PTEN inactivation, and the use of these two genetic events 
may help predict the clinical prognosis. Translocations between the TMPRSS2-ERG genes 
creates a constitutively active transcription factor that is uniquely found in approximately 50% of 
prostate tumors and thought to be essential for the carcinogenesis in this subset of tumors.[6-9] 
Large series of prostate cancer estimate PTEN inactivation occurs in approximately 18-23% of 
all tumors [6,9,10], and its loss allows for uninhibited activation of the PI3K/Akt/mTOR 
pathway and additional downstream targets. Mouse models that constitutively over-expressed 
ERG in a PTEN null background lead to highly penetrant prostate cancer that that arises much 
quicker than PTEN loss alone.[11] PTEN deletions have been associated with higher histologic 
grades, lymph node metastases and lower overall survival in TMPRSS2-ERG gene fusion 
positive and negative cancers.[6,9,12,13] Prostate cancers that lack TMPRSS2-ERG gene fusions 
and PTEN deletion have been shown to have a better prognosis, and the use of both gene 
rearrangements is the basis of a predictive model of disease reoccurrence.[14]  
Clinical course of T1a prostate cancers (tumors found incidentally in transurethral 
resection without clinically suspected tumor, making up <5% of the tissue) is variable with long 
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term followup.[15-17] The status of TMPRSS2-ERG fusions and PTEN and have not been well 
characterized in transition zone T1a tumor. These tumors typically do not receive treatment, but 
have the risk of progression to clinically significant disease. We assessed the genetic status of 
TMPRSS2-ERG fusions and PTEN in order to further understand the biology of prostate cancer 
in an attempt to find genetic predictors of aggressive behavior. Here we describe the frequency 
of PTEN inactivation and TMPRSS2-ERG gene fusions and their relationship in T1a tumors 
using human prostatic tissue removed by transurethral resection of the prostate (TURP). We 
analyzed 54 cases of Gleason score 7 or lower adenocarcinoma for the status of PTEN and 
TMPRSS2-ERG using both immunohistochemistry and fluorescence in situ hybridization.  
 
Methods 
Patients  
We identified 54 T1a prostate adenocarcinomas by reviewing TURP specimens from 
participating institutions (Indiana University, Indianapolis, USA; Polytechnic University of the 
Marche Region, United Hospitals, Ancona, Italy; Case Western Reserve University, Cleveland, 
USA; Henry Ford Health System, Detroit, MI; Cordoba University, Cordoba, Spain) between 
2003 and 2014. All TURP samples with carcinoma diagnoses were reviewed by 2 anatomic 
pathologists (KWF and LC) to confirm tumor volume was less than 5% of the resected specimen, 
meeting the criteria of the American Joint Committee on Cancer for T1a tumor staging. No 
Gleason grade 8 or higher cancers were found to have less than 5% involvement of a TURP 
sample. This research was approved by the Institutional Review Board.  
  
Immunohistochemistry 
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We evaluated the status of ERG and PTEN proteins in formalin-fixed, paraffin-embedded 
tissue using immunohistochemical staining. Briefly, 4-µm-thick sections were heated in a PT 
module (DAKO, Carpinteria, CA) in Tris/EDTA (pH 9.0) for 20 minutes and then cooled down 
to room temperature. Samples were incubated at 1:200 dilution with PTEN antibody (rabbit 
monoclonal antibody, clone D4.3 XP, Cell signaling technology, Danvers, MA) or ready-to-use 
ERG antibody (rabbit monoclonal antibody, clone EP111, Dako Carpinteria, CA.) for 30min and 
20min. respectively. This was followed by incubations with DAKO Envision Flex+rabbit linker, 
Envision HRP, and DAB+ chromogen. All other step followed the manufacturers’ provided 
protocols. A tumor was considered to have PTEN protein loss if the intensity of cytoplasmic 
staining was markedly decreased or entireley lost in more than 10% of tumor cells compared 
with surrounding benign glands.[18-21]. ERG nuclear staining was scored as positive or negative 
and any nuclear staining of ERG was considered as indicative of ERG expression.[22,23]  
 
Fluorescence in situ hybridization 
Four-micrometer-thick sections were obtained from formalin-fixed, paraffin-embedded 
specimen blocks and deparaffinized with two 15-minute washes in xylene, subsequently washed 
twice with 100% ethanol for 10 minutes each, and air-dried. The sections were heated at 95°C in 
0.1 mM citric acid (pH 6) solution (Invitrogen, Carlsbad, CA) for 10 min, rinsed with distilled 
water for 3 min, and washed with 2x saline-sodium citrate (SSC) for 5 min. Tissue digestion was 
performed by applying 0.4 ml of pepsin (Sigma, St Louis, MO, USA) solution (4 mg/ml in 0.9% 
NaCl in 0.01N HCl) to each slide and incubating the slides in a humidified box for 40 min at 
37°C. The slides were rinsed with distilled water for 5 min, washed with 2xSSC for 5 min, and 
then air dried.  
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For PTEN copy number assay, a probe cocktail containing BAC clone RP11-383D9-Orange 
(PTEN, Empire Genomics, Buffalo, NY, USA) and CEP10-Green (Abbott Molecular, Abbott 
Park, IL) diluted 1:25 in tDenHyb2 (Insitus, Albuquerque, NM, USA). The genomic status of 
ERG was determined using 3 colored FISH using a TMPRSS2 aqua probe, a 5’ ERG green probe, 
and a 3’ gold ERG probe. Five microliters of diluted probe were applied to each slide. Coverslips 
were placed over the slides and sealed with rubber cement. The slides were denatured at 80°C for 
10 min and hybridized at 37°C overnight. The coverslips were removed and the slides were 
extensively washed with two 0.1xSSC/1.5M urea solutions at 45°C for 20 min, in 2xSSC at 45°C 
for 10min, and then in 2xSSC/0.1% NP40 at 45°C for 10 min. Finally, the slides were washed 
with 2xSSC at room temperature for 5 min, air dried, counterstained with 10 µl DAPI/Antifade 
(DAPI in Fluorguard, 0.5 g/ml, Insitus, Albuquerque, NM, USA) and sealed with nail polish. 
    The hybridized slides were observed and documented using a MetaSystem imaging system 
and ISIS software (Belmont, MA, USA) under x100 oil objective. The images were acquired 
with a CoolCube 1 camera (MetaSystem) and analyzed with Isis software (Belmont, MA). The 
following filters were used: SP-100 for DAPI, FITC MF-101 for spectrum green, Gold 31003 for 
spectrum orange. Signals from each color channel (probe) were counted under false color, with 
computerized translation of each color channel into blue, green, red, or aqua. Four sequential 
focus stacks with 0.3 µm intervals were acquired and integrated into a single image to reduce 
thickness-related artifacts. For each case, 100 non-overlapping cancer cells nuclei were 
evaluated. Preparations were considered valid if >90% of the cells showed bright signals. 
Hemizygous deletion of PTEN was defined as ≥50% of tumor nuclei containing one PTEN 
signal, and with the presence of CEP 10 signals. Homozygous deletion of PTEN was defined as 
in ≥30% of tumor nuclei simultaneous loss of both PTEN signal, and with the presence of CEP 
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10 signals.[13,24,25] Cases with ERG signal abnormalities in ≥20% of the tumor cell population 
were considered to be positive.[22,26]  
 
Statistical methods 
Fisher exact tests were used to determine the association between PTEN protein 
expression and allele deletion status. Statistical significance was defined as p < 0.05 and all p 
values were two-sided. 
 
Results 
The samples we analyzed were composed of 51 Gleason grade 3+3=6 and 3 Gleason 
grade 3+4=7 prostatic adenocarcinomas, all of which involved less than 5% volume per sample. 
The average age was 73 years (range: 52-92 years), and the average specimen mass was 58 
grams (range: 3-260 g) (Table 1). 
We found ERG rearrangement by FISH in 2 of 54 tumors (4%), one with corresponding 
protein overexpression by immunohistochemistry (Figure 1 and Table 1). We did not find any 
ERG overexpression or ERG rearrangements in adjacent benign prostatic glands. We found 
PTEN protein loss in 13 of 54 (24%) tumors using immunohistochemistry (Figure 2 and Table 
2). The PTEN protein loss status was highly correlated with PTEN allele deletion detected by 
FISH method (p=0.0001). Nine of the 13 cases (69%) with PTEN protein loss showed 
hemizygous deletion of PTEN by FISH. No homozygous PTEN deletion was observed. We did 
not find any PTEN protein loss in adjacent benign tissue.  
 
Discussion 
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TMPRSS2-ERG rearrangements can be found in approximately 50% of peripheral zone 
tumors [6-9] and large series of prostate cancer estimate PTEN inactivation to occur in 
approximately 18-23% of all tumors [6,9,10]. Using a combination of IHC and FISH, we found 
that ERG overexpression (4%) is dramatically underrepresented in small T1a transition zone 
tumors. However, PTEN inactivation (24%) in stage T1a prostate cancer was similar to the most 
recent estimates of PTEN inactivation in large series of prostate cancer [6,9,10]. 
It is possible that our study using only immunohistochemistry and FISH studies might 
underestimate the true incidence of genetic PTEN inactivation, but other studies has shown a 75-
89% correlation between FISH and IHC.[6,18] A recent study has shown inactivating point 
mutations of PTEN occur in approximately 5% of samples, which would not be detected by 
FISH and IHC.[6] Even a minor upward adjustment in our estimation of PTEN inactivation in 
T1a tumors would not change the conclusion that the prevalence is similar to PTEN inactivation 
seen in peripheral zone tumors. PTEN deletion has been associated with a worse prognosis in 
peripheral zone cancers and the similar frequency of PTEN inactivation in our sample does not 
seem to be an explanation for the indolent behavior of transition zone tumors.[6,9,18,24] Larger 
data sets and prospective studies will be needed to assess the prognostic value of PTEN 
inactivation in transition zone tumors. More recent work has been done to optimize PTEN 
analysis by immunohistochemistry and that optimized four color FISH probes have been 
identified and applied in other cohorts of prostate cancer. These optimized assays have now been 
applied to a large multicenter cohort with rigorous statistical analysis. [21] The development of a 
clinical-grade, automated, and cost effective PTEN assay will facilitate further validation of 
PTEN as an important prognostic and predictive biomarker for prostate cancer.   
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TMPRSS2-ERG fusion proteins are seen in approximately 50% of prostate cancers, but 
these were dramatically underrepresented in our sample population. ERG is a member of the 
ETS family, which has 28 unique genes. Of these, FLI, ERG, ETV1 and ETV4 are commonly 
deregulated in cancer.[27] TMPRSS2 and ERG are located within 3 megabases of each other on 
chromosome 21, and large deletions, and less commonly translocations, help to explain the high 
prevalence of fusions involving ERG compared to other ETS family members.[28] ETS family 
members can also be fused to proteins other than TMPRSS2, but represent a tiny fraction of all 
fusion proteins.[29-32] ERG immunohistochemistry has approximately 85% sensitivity and 
specificity for ERG fusions confirmed by RT-PCR and can be used in conjunction with ERG 
FISH to increase confidence in identifying ERG fusion positive tumors up to 98.5%.[6,7,33,34] 
It is possible in our sample population that a different ETS family member or different partner 
other than TMPRSS2 is involved in rearrangements in some cases; however, this is unlikely to 
add a substantive fraction of ETS family-rearranged tumors, since other partners have a much 
lower incidence than ERG and TMPRSS2 was not aberrantly disrupted in any sample. 
The best defined role for TMPRSS2-ERG fusions appears to be in the initiation of 
carcinogenesis, as it is found in early lesions and typically homogenously maintained within high 
grade tumors.[22,35-37] However, there are emerging molecular pathways to carcinogenesis that 
appear to be mutually exclusive to ERG fusions: 1) Speckle-type POZ protein (SPOP) is the 
most commonly mutated gene in prostate cancer and acts as an E3 ubiquitin ligase adaptor that 
directly binds target proteins and promotes their cullin 3-dependent ubiquitination and 
proteolysis.[38,39] Mutations in SPOP occur in the substrate binding domain and prevent the 
interaction with target proteins leading to increased levels of oncogenic steroid receptor co-
activator-3 (SRC-3/AIB1) and the androgen receptor.[40-42]; 2) Chromodomain helicase DNA-
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binding protein 1 (CHD1) is a tumor suppressor located at 5q21 that is inactivated, mainly 
through deletion, in 13-26% of prostate cancers.[43-45] The loss of CHD1 inhibits AR-
dependent signaling, which is required for TMPRSS2-ETS family gene rearrangements, so CHD1 
inactivation and TMPRSS2-ETS family gene rearrangements are seldom identified in the same 
tumor.[46,47] Inactivation of CHD1 forces the developing cancer into a pathway of 
carcinogenesis that does not require TMPRSS2-ETS family rearrangements. Deletion of CHD1 
alone in cell line models of prostate cancer was insufficient to cause invasive carcinoma, and the 
additional genetic events required for malignancy remain undetermined [44]; 3) Serine peptidase 
inhibitor, Kalal type 1 (SPINK1) is overexpressed in approximately 6% of all prostate cancers 
and 10% of TMPRSS2-ETS family gene fusion negative cancers.[48,49] SPINK1 overexpression 
appears largely to be mutually exclusive with ERG fusion, and is highly associated with 6q15 
and 5q21 deletions, suggesting it represents a unique pathway to carcinogenesis.[49] SPINK1 
overexpressing tumors as sensitive to inhibition of EGFR and may be clinically amenable to 
targeted inhibition of EGFR.[50,51] 
PTEN inactivation is relatively common compared to ERG rearrangement in T1a prostate 
cancers. The low prevalence of TMPRSS2-ERG gene fusion positive cancers in our study 
suggests that the alternative molecular pathways to carcinogenesis may play a crucial role in T1a 
cancers. Further study is needed to define the role of these alternate pathways to tumorigenesis 
and assess their role in prognosis and targeted treatment regimens.  
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Figure Legends 
Figure 1 Histological and ERG status by immunohistochemistry and ERG FISH in T1a prostate 
cancer: Only a single example (1 of 54, 2%) of T1a prostate cancer (A) exhibited ERG protein 
expression by immunohistochemistry (B), and only 2 of 54 (4%) demonstrated ERG 
rearrangement by FISH (C). In each nucleus, one red-green-aqua signal triplet is closely 
juxtaposed, whereas the other copy exhibits a widely separated green signal (C). In most T1a 
prostate cancers (D), neither ERG protein expression (E) nor ERG rearrangement was present 
(F), the latter evidenced by two copies of closely juxtaposed red-green-aqua signals. 
 
Figure 2 PTEN loss in a subset of T1a prostate cancers: Among the 54 T1a prostate cancers (A), 
76% exhibited normal PTEN protein expression (B) and normal PTEN copy number (C) as 
indicated by 2 red (PTEN) and 2 green (CEP10) signals. A subset of 24% of T1a prostate cancers 
(D) showed loss of PTEN expression (E), which correlated with hemizygous PTEN deletion as 
indicated by the loss of 1 red signal (PTEN) and 2 normal green signals (CEP10). 
Table 1. Immunohistochemical and FISH assessment of ERG status 
ERG STATUS IHC + IHC - Total 
FISH Rearrangement + 1 1 2 
FISH Rearrangement - 0 52 52 
Total 1 53 54 
 
IHC: immunohistochemistry. 
 
Table 2. Immunohistochemical and FISH assessment of PTEN status 
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PTEN STATUS IHC + IHC - Total 
Deletion - 41 4 45 
Deletion + 0 9 9 
 41 13 54 
 
IHC: immunohistochemistry. 
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Figure 1 composite   . 
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Figure 2 composite  . 
 
